Baidu
map

ASCO:趋化因子在预测t细胞炎症和对不同肿瘤类型免疫检查点抑制反应中的作用

2022-06-05 MedSci原创 MedSci原创

4个趋化因子组合有可能选择更广泛的可能受益于ICI的患者。

免疫检查点抑制剂(ICI)对某些癌症非常有效。新的T细胞炎症预测因子可能会识别出更广泛的具有ICI反应性的肿瘤子集。此前,来自加拿大McGill的学者已经确定了四个趋化因子(CCL4、CCL5、CXCL9、CXLC10)能够预测原发性和转移性胰腺肿瘤的T细胞炎症表型。

近期在ASCO2022大会上,该组学者进一步测试这4个趋化因子特征是否能预测其他类型肿瘤的T细胞炎症和对ICI的反应。研究人员利用来自癌症基因组图谱25种肿瘤类型的6455名患者的匹配基因组和转录组数据,搜索了4个趋化因子特征与抗肿瘤免疫力指标之间的关联。此外还测试了这一特征与DNA损伤修复缺陷标志物的关联。

大多数肿瘤类型显示出上述4个趋化因子和癌症-免疫循环的转录标志的高表达的亚群。睾丸生殖细胞瘤、宫颈鳞状细胞癌和头颈鳞状细胞癌是该特征的最强表达者。免疫调节基因,包括PD-L1、PD-1、TIM3、LAG3、TIGIT、CTLA-4和FASLG,在4个趋化因子队列中明显过度表达(P<0.05)。

参与癌症-免疫循环过程的基因组,包括MHC I的表达和细胞溶解活性,在4个趋化因子队列中被上调(P<0.05)。虽然肿瘤突变负担(TMB)和4个趋化因子的表达在整个肿瘤组织学类型中存在整体关系(rho=0.42,p=0.02),但高TMB仅与4个趋化因子肿瘤的一个子集有关。在接受ICI治疗的患者中,那些患有4个趋化因子肿瘤的患者的中位进展时间(104天对71天,p=0.013)和总生存期(391天对195天,p=0.016)更长。在预测总生存期方面,4个趋化因子特征的表现优于TMB。

综上,各种类型的肿瘤都存在T细胞炎症患者亚群,因此可能对ICI有良好的反应。4个趋化因子组合有可能选择更广泛的可能受益于ICI的患者。

 

参考文献:

Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types. First Author: Joan Miguel Romero, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046601, encodeId=4987204660195, content=<a href='/topic/show?id=4499e795592' target=_blank style='color:#2F92EE;'>#细胞炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77955, encryptionId=4499e795592, topicName=细胞炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Nov 06 14:39:27 CST 2022, time=2022-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939418, encodeId=b6c71939418d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 22 20:39:27 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340616, encodeId=7ef0134061613, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Jun 01 13:39:27 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553414, encodeId=c6b9155341482, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Wed Jun 01 13:39:27 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046601, encodeId=4987204660195, content=<a href='/topic/show?id=4499e795592' target=_blank style='color:#2F92EE;'>#细胞炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77955, encryptionId=4499e795592, topicName=细胞炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Nov 06 14:39:27 CST 2022, time=2022-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939418, encodeId=b6c71939418d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 22 20:39:27 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340616, encodeId=7ef0134061613, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Jun 01 13:39:27 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553414, encodeId=c6b9155341482, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Wed Jun 01 13:39:27 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-09-22 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046601, encodeId=4987204660195, content=<a href='/topic/show?id=4499e795592' target=_blank style='color:#2F92EE;'>#细胞炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77955, encryptionId=4499e795592, topicName=细胞炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Nov 06 14:39:27 CST 2022, time=2022-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939418, encodeId=b6c71939418d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 22 20:39:27 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340616, encodeId=7ef0134061613, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Jun 01 13:39:27 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553414, encodeId=c6b9155341482, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Wed Jun 01 13:39:27 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046601, encodeId=4987204660195, content=<a href='/topic/show?id=4499e795592' target=_blank style='color:#2F92EE;'>#细胞炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77955, encryptionId=4499e795592, topicName=细胞炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Nov 06 14:39:27 CST 2022, time=2022-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939418, encodeId=b6c71939418d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 22 20:39:27 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340616, encodeId=7ef0134061613, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Jun 01 13:39:27 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553414, encodeId=c6b9155341482, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Wed Jun 01 13:39:27 CST 2022, time=2022-06-01, status=1, ipAttribution=)]

拓展阅读

2022 ASCO:复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失,一项回顾性队列研究

分析探讨复发或难治性B细胞非霍奇金淋巴瘤中,CD20和CD19表达缺失的影响。

2022 ASCO:戈利昔替尼用于治疗难治性或复发性外周T细胞淋巴瘤的I期/II期研究

报告了正在进行的戈利昔替尼在外周T细胞淋巴瘤中的I/II期研究 (NCT04105010) 的初步数据。

2022 ASCO:诱导方法对新诊断急性髓系白血病(AML)老年人干细胞移植后(SCT)结局的影响

讨论不同诱导方案对新诊断急性髓系白血病(AML)老年人干细胞移植后(SCT)结局的影响。

2022 ASCO:基于查尔森合并症指数(CCI)预测急性早幼粒细胞白血病(APL)的早期死亡率和总生存期

评估查尔森合并症指数(CCI)作为60岁以下急性早幼粒细胞白血病(APL)患者1个月死亡率和总生存期(OS)的预测因子。

2022 ASCO:罗沙司他治疗非髓系恶性肿瘤化疗患者贫血的开放标签2期研究

评估罗沙司他对接受骨髓抑制化疗的贫血患者的疗效和安全性。

2022 ASCO:一种新型抗 PD-1 抗体Serplulimab,化疗疗效和安全性研究的3期研究

Serplulimab是一种新型人源化单克隆抗PD-1抗体,与化疗联合用于先前未治疗的ES-SCLC患者,对疗效和安全性进行评估。

Baidu
map
Baidu
map
Baidu
map